Green Equity Holdings, Inc. (otcqb:CXTO) (the "Company") is pleased to report that we signed a Letter of Intent (LOI) with pH Pharmaceutical, Inc. ("PH"), a pharmaceutical company based in Washington, DC. PH is focused on the commercial application and licensing patented phl-100 technology. The LOI, signed on March 8, 2012, begins Green Equity's due diligence process, which includes the acquisition of the exclusive worldwide rights to the patented phl-100 technology. This unique technology has been FDA-approved for Over-the-Counter use in such formulated products for healthy skin and hair care, acne and anti-fungal treatments, and more.Christopher Pearce, one of the founding principals of pH Pharmaceutical, Inc., will assume the duties as CEO and President upon the close of the transaction. Prior to co-founding PH in December 2007, Mr. Pearce served as Chairman and CEO of The Cannon Group, an NYSE-listed company, from 1991 to 1994. Raimundo Dias, CEO of Green Equity Holdings, Inc. said, "Mr. Pearce has significant experience in sales, marketing, finance and management. He brings a powerful combination of business experience, proven results and inspirational leadership to successfully run the global business strategies of PH."As part of the above contemplated transaction, the current CEO, President and Sole Director of PH, Noreen Griffin, is resigning to seek other opportunities. Mr. Pearce thanks Ms. Griffin for her support and dedication to the company over the last couple of years.SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent Green Equity expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," or "expects," used in the Company's press releases and periodic reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission ("SEC"), are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Green Equity undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment